Canada
· Delayed Price · Currency is CAD Revive Therapeutics Company Description
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases.
The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation.
The company is based in Toronto, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Michael Frank |
Contact Details
Address: The Canadian Venture Building Toronto, Ontario M5C 1P1 Canada | |
| Phone | 888-901-0036 |
| Website | revivethera.com |
Stock Details
| Ticker Symbol | RVV |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | CAD |
| ISIN Number | CA7615161030 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Frank | Chairman and Chief Executive Officer |
| Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA, CPA | Chief Financial Officer |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Scientific Officer Consultant |
| Dr. Onesmo Mpanju Ph.D. | Chief Regulatory Affairs Consultant |